Talis Biomedical: Rob Kelley, Brian Blaser

Talis Biomedical has promoted Rob Kelley, its chief commercial officer, to CEO and director.

He replaces Brian Blaser who has stepped down as the firm's president, CEO, and director for personal reasons.

Kelley has served as the company’s chief commercial officer since September 2020. Prior to joining Talis, he was vice president of sales and commercial development at Genalyte and vice president of marketing at Cardiff Oncology (formerly Trovagene). Earlier, Kelley held various positions of increasing responsibility with Illumina, including global sales manager for clinical applications of next-generation sequencing and director of market development for new and emerging opportunities.

In August, Talis had announced that Brian Coe, then its president, CEO, and director, was stepping down, and it appointed Kim Popovits as interim CEO.

And on Nov. 15, the point-of-care testing firm had announced Blaser as its director, president, and CEO effective Dec. 1.